BioSpace News Archive

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for four generics products, including vasopressin injection 1mL (single-dose).

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2022.

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2022 and provides a business update.

Veracyte, Inc. announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately.

Ensysce Biosciences, Inc., a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, reported financial results for the second quarter 2022.

Marker Therapeutics, Inc. (Nasdaq: MRKR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2022.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its second quarter 2022 financial results will be reported on Thursday, August 18, 2022 before the open of the financial markets.

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced the commencement of a proposed public offering of 1,000,000 shares of its common stock.

Henry Schein, Inc. announced the passing of E. Dianne Rekow, DDS, Ph.D., a member of the Company’s Board of Directors since 2014 and a leader in the development of digital dentistry.

Sonoma Pharmaceuticals, Inc.,a global healthcare leader developing and producing stabilized hypochlorous acid products for a wide range of applications, including wound care, eye, oral and nasal care, and dermatological conditions, announced financial results for its first fiscal quarter ended June 30, 2022.